Percheron Therapeutics (ASX:PER) submitted a non-binding proposal to a pharmaceutical company to in-license a new drug development program focusing on a rare neurological disease, according to a Monday Australian bourse filing.
The proposal remains subject to further negotiations, as well as the execution of a definitive agreement, the filing said.
The firm estimated that at this stage it would take eight to 12 weeks to negotiate and sign a definitive agreement.
It plans to continue to evaluate alternative opportunities in parallel to the proposal.
The firm's shares jumped 8% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。